Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

Evaluate the expected performance of Regeneron (REGN) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key ...

Who are the leading players in the Evkeeza market? Key players in the Evkeeza market include the notable Regeneron Pharmaceuticals Inc., contributing significantly to the market growth.

Please note that Evkeeza was originally discovered and developed by Regeneron Pharmaceuticals REGN. In 2022, Ultragenyx signed a licensing agreement with Regeneron for Evkeeza to treat HoFH.

Regeneron Pharmaceuticals, Inc. announced positive results from the phase 3 C-POST trial, which demonstrated that adjuvant treatment with PD-1 inhibitor Libtayo (cemiplimab) led to a statistically ...

Learn more about whether Ultragenyx Pharmaceutical Inc. or Vericel Corporation is a better investment based on AAII's A+ ...

Regeneron Pharmaceuticals, Inc. (REGN) Securities Class Action: The litigation is focused on the propriety of Regeneron’s statements about its compliance with applicable rules and regulations ...

In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against other best depressed stocks to invest in now. The US stocks ended 2024 with a ...

During the last three months, 18 analysts shared their evaluations of Regeneron Pharmaceuticals REGN, revealing diverse outlooks from bullish to bearish. The table below offers a condensed view of ...

Alaina Pinto of The Wheatley School in East Williston School District was announced as one of the top 300 scholars from across the nation in the Regeneron Science Talent Search 2025, the nation ...

Forty high school students, including four from Nassau County, have been selected as finalists for the annual Regeneron Science Talent Search. Melody Hong of MacArthur High School in Levittown ...